These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 31639020)

  • 21. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.
    Hermisson M; Klumpp A; Wick W; Wischhusen J; Nagel G; Roos W; Kaina B; Weller M
    J Neurochem; 2006 Feb; 96(3):766-76. PubMed ID: 16405512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decitabine nanoconjugate sensitizes human glioblastoma cells to temozolomide.
    Cui Y; Naz A; Thompson DH; Irudayaraj J
    Mol Pharm; 2015 Apr; 12(4):1279-88. PubMed ID: 25751281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition.
    Liu T; Li A; Xu Y; Xin Y
    Oncol Rep; 2019 Mar; 41(3):1883-1892. PubMed ID: 30664175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
    Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
    Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted radiosensitization by the Chk1 inhibitor SAR-020106.
    Borst GR; McLaughlin M; Kyula JN; Neijenhuis S; Khan A; Good J; Zaidi S; Powell NG; Meier P; Collins I; Garrett MD; Verheij M; Harrington KJ
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1110-8. PubMed ID: 22981708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transcriptomic Profiling of DNA Damage Response in Patient-Derived Glioblastoma Cells before and after Radiation and Temozolomide Treatment.
    Lozinski M; Bowden NA; Graves MC; Fay M; Day BW; Stringer BW; Tooney PA
    Cells; 2022 Apr; 11(7):. PubMed ID: 35406779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GADD45A plays a protective role against temozolomide treatment in glioblastoma cells.
    Wang HH; Chang TY; Lin WC; Wei KC; Shin JW
    Sci Rep; 2017 Aug; 7(1):8814. PubMed ID: 28821714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
    Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
    World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-tumour immune response in GL261 glioblastoma generated by Temozolomide Immune-Enhancing Metronomic Schedule monitored with MRSI-based nosological images.
    Wu S; Calero-Pérez P; Villamañan L; Arias-Ramos N; Pumarola M; Ortega-Martorell S; Julià-Sapé M; Arús C; Candiota AP
    NMR Biomed; 2020 Apr; 33(4):e4229. PubMed ID: 31926117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide.
    Forte IM; Indovina P; Iannuzzi CA; Cirillo D; Di Marzo D; Barone D; Capone F; Pentimalli F; Giordano A
    Int J Oncol; 2019 Jun; 54(6):2189-2199. PubMed ID: 31081046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decitabine, a DNA methyltransferases inhibitor, induces cell cycle arrest at G2/M phase through p53-independent pathway in human cancer cells.
    Shin DY; Sung Kang H; Kim GY; Kim WJ; Yoo YH; Choi YH
    Biomed Pharmacother; 2013 May; 67(4):305-11. PubMed ID: 23582784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action.
    Punganuru SR; Artula V; Zhao W; Rajaei M; Deokar H; Zhang R; Buolamwini JK; Srivenugopal KS; Wang W
    Cells; 2020 Jul; 9(7):. PubMed ID: 32630235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination therapy of cold atmospheric plasma (CAP) with temozolomide in the treatment of U87MG glioblastoma cells.
    Gjika E; Pal-Ghosh S; Kirschner ME; Lin L; Sherman JH; Stepp MA; Keidar M
    Sci Rep; 2020 Oct; 10(1):16495. PubMed ID: 33020527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced sensitivity of celecoxib in human glioblastoma cells: Induction of DNA damage leading to p53-dependent G1 cell cycle arrest and autophagy.
    Kang KB; Zhu C; Yong SK; Gao Q; Wong MC
    Mol Cancer; 2009 Aug; 8():66. PubMed ID: 19706164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological Strategy for Selective Targeting of Glioblastoma by Redox-active Combination Drug - Comparison With the Chemotherapeutic Standard-of-care Temozolomide.
    Sumiyoshi A; Shibata S; Zhelev Z; Miller T; Lazarova D; Zlateva G; Aoki I; Bakalova R
    Anticancer Res; 2021 Dec; 41(12):6067-6076. PubMed ID: 34848461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NKG2D-Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma.
    Weiss T; Schneider H; Silginer M; Steinle A; Pruschy M; Polić B; Weller M; Roth P
    Clin Cancer Res; 2018 Feb; 24(4):882-895. PubMed ID: 29162646
    [No Abstract]   [Full Text] [Related]  

  • 37. Chk1 and Wee1 control genotoxic-stress induced G2-M arrest in melanoma cells.
    Vera J; Raatz Y; Wolkenhauer O; Kottek T; Bhattacharya A; Simon JC; Kunz M
    Cell Signal; 2015 May; 27(5):951-60. PubMed ID: 25683911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Silencing SATB1 overcomes temozolomide resistance by downregulating MGMT expression and upregulating SLC22A18 expression in human glioblastoma cells.
    Yang B; Ma YB; Chu SH
    Cancer Gene Ther; 2018 Dec; 25(11-12):309-316. PubMed ID: 30140041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autophagy-based unconventional secretion of HMGB1 in glioblastoma promotes chemosensitivity to temozolomide through macrophage M1-like polarization.
    Li Z; Fu WJ; Chen XQ; Wang S; Deng RS; Tang XP; Yang KD; Niu Q; Zhou H; Li QR; Lin Y; Liang M; Li SS; Ping YF; Liu XD; Bian XW; Yao XH
    J Exp Clin Cancer Res; 2022 Feb; 41(1):74. PubMed ID: 35193644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma.
    Tiek DM; Rone JD; Graham GT; Pannkuk EL; Haddad BR; Riggins RB
    Sci Rep; 2018 May; 8(1):7222. PubMed ID: 29740146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.